New Product Tracking

Drug Intelligence can rapidly and accurately monitor post-launch performance of newly introduced products to get better insights on any course corrections (at a strategic or tactical level) and the evolving competitive dynamics.

For any new product, such an audit will track the patients post launch and validate patient profile, dosage and the therapies that were substituted by this new entry. In addition, we have the ability to monitor metrics such as usage by specialty or hospital ward, indications and share of market.